Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.78 |
| ▸ | ITGA2B | P08514 | 19/20 | 0.78 |
| ▸ | ITGAV | P06756 | 16/20 | 0.78 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469959 | 0.94 | ITGB3 (0.78) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL7467243 | 0.92 | ITGB3 (0.67) | ITGB3ITGA2BITGAV | |
| SCHEMBL7465379 | 0.92 | ITGB3 (0.79) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL7052828 | 0.89 | ITGB3 (0.76) | ITGB3ITGA2BITGAV | |
| SCHEMBL7465504 | 0.88 | ITGB3 (0.62) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL6497886 | 0.88 | ITGB3 (0.66) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL7461955 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BITGAV | |
| SCHEMBL382753 | 0.87 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL30856557 | 0.87 | ITGB3 (1.00) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL7457802 | 0.87 | ITGB3 (0.60) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | claimed |
| US-7176199-B2 | Aryl-substituted alicyclic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1371646-A1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106622-A1 | Aryl-substituted alicylic compound and medical composition comprising the same | ITGB3, ITGB1, ITGAL | ITGB3 1/4885ITGA2B 12/4885ITGAV 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.